REDX PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9 GBX | -10.00% |
|
-25.00% | -59.09% |
| Apr. 19 | Redx Pharma shareholders approve AIM delisting plans | AN |
| Apr. 19 | Redx Pharma Gets Shareholder Approval for Delisting from AIM | MT |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10.12 | 107.4 | 235.4 | 188.3 | 87.08 | 35.01 | - |
| Enterprise Value (EV) 1 | 10.12 | 100.3 | 220.1 | 150.2 | 84.72 | 30.2 | 74.13 |
| P/E ratio | -2.35 x | -10.5 x | -10.2 x | -9.26 x | -2.63 x | -1.34 x | -0.71 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.23 x | 18.9 x | 23.5 x | 10.1 x | 20.7 x | 2.8 x | - |
| EV / Revenue | 3.23 x | 17.6 x | 21.9 x | 8.04 x | 20.2 x | 2.42 x | - |
| EV / EBITDA | - | -13.3 x | -11.5 x | -9.77 x | -2.78 x | -1.17 x | -1.49 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 126,478 | 190,009 | 275,282 | 333,353 | 334,911 | 388,986 | - |
| Reference price 2 | 0.0800 | 0.5650 | 0.8550 | 0.5650 | 0.2600 | 0.0900 | 0.0900 |
| Announcement Date | 3/16/20 | 1/27/21 | 1/27/22 | 12/20/22 | 12/15/23 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.131 | 5.685 | 10.04 | 18.69 | 4.202 | 12.5 | - |
| EBITDA 1 | - | -7.536 | -19.11 | -15.38 | -30.47 | -25.92 | -49.67 |
| EBIT 1 | - | -8.518 | -19.74 | -16.27 | -31.43 | -26.8 | -50.55 |
| Operating Margin | - | -149.83% | -196.76% | -87.03% | -747.91% | -214.4% | - |
| Earnings before Tax (EBT) 1 | - | -9.168 | -21.44 | -17.8 | -32.79 | -26.81 | -50.56 |
| Net income 1 | - | -9.213 | -21.58 | -18 | -33.16 | -26.14 | -49.3 |
| Net margin | - | -162.06% | -215.01% | -96.33% | -789.05% | -209.12% | - |
| EPS 2 | -0.0340 | -0.0540 | -0.0840 | -0.0610 | -0.0990 | -0.0672 | -0.1267 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 1/27/21 | 1/27/22 | 12/20/22 | 12/15/23 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 39.1 |
| Net Cash position 1 | - | 7.04 | 15.3 | 38.1 | 2.36 | 4.81 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.7876 x |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -0.0800 | -0.0300 | -0.1000 | -0.0600 | -0.1100 |
| Capex 1 | - | 0.06 | 0.75 | 0.26 | - | 0.26 | 0.26 |
| Capex / Sales | - | 1.04% | 7.51% | 1.4% | - | 2.08% | - |
| Announcement Date | 3/16/20 | 1/27/21 | 1/27/22 | 12/20/22 | 12/15/23 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.09
GBP
Average target price
1.3
GBP
Spread / Average Target
+1,344.44%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -59.09% | 43.61M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- REDX Stock
- Financials Redx Pharma Plc
